Poster Abstracts • OFID 2018:5 (Suppl 1) • S199 were conducted three times weekly. During these rounds, all Foley catheters, central lines, and CDI cases were discussed and a root cause analysis was performed for healthcare-associated infections (HAIs). CDI standardized infection ratio (SIR) was the primary metric tracked to assess outcome and trends by quarter over a two year period were evaluated.
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No reported disclosures. Methods. All patients initiating HAART at the clinic from 2009 to 2017 were included in the analysis. Exposure to HAART was defined as concurrent receipt of at least two nucleoside reverse transcriptase inhibitors (NRTI) plus at least one PI, non-nucleoside reverse transcriptase inhibitor (NNRTI) or INSTI. The effects of sex, race, and ethnicity on changes in BMI (kg/m 2 ) per year on HAART were examined using mixed-effects random regression.
Integrase Inhibitor-Based HAART Is Associated with Greater BMI Gains in
Results. Among the 4,048 patients initiating HAART, 69% were male, 53% Black (B), 28% Hispanic (H), and 16% non-Hispanic Whites (NHW). Mean age was 46.3 years (SD 11.9) and mean BMI was 27.0 (6.4). Median follow-up time on HAART was 6.7 years. Cumulative exposure to NNRTI, PI, and INSTIbased HAART were 3,546, 6,184, and 3,090 person-years respectively. The BMI slope per year of HAART exposure by regimen type, sex, race, and ethnicity are presented in Table 1 and Figure 1 . There was no significant interaction between sex and race/ethnicity on BMI. Proportion of overweight/obese (BMI ≥ 25) increased from 51% at HAART initiation to 65% at year 3 (P < 0.001) (Figure 2 ). Background. GS-CA2, an analog of GS-CA1, is a novel and selective inhibitor of HIV-1 capsid function. Safety and pharmacokinetics (PK) of GS-CA2 is currently being evaluated in healthy human subjects. Herein, we present the anti-HIV activity and nonclinical PK of GS-CA2, demonstrating its potential as a first-in-class long-acting antiretroviral agent.
Methods. GS-CA2 antiviral activity was evaluated in MT-4 cells and in human peripheral blood mononuclear cells (PBMCs) acutely infected with HIV-1 (IIIb) and clinical HIV-1 isolates, respectively. Standard in vitro methods were used to characterize compound lipophilicity (LogD), solubility and relative binding to cell culture and plasma proteins. Metabolic stability was assessed in cryopreserved hepatocytes. GS-CA2 PK parameters following intravenous and subcutaneous (SC) administration were assessed in rat and dog. GS-CA2 plasma concentrations were determined by HPLC-MS/MS.
Results. GS-CA2 showed potent and selective anti-HIV activity in MT-4 cells (EC 50 = 0.1 nM; CC 50 = 26.6 µM). In PBMCs, GS-CA2 displayed a mean EC 50 of 0.05 nM (0.02-0.16 nM) against 23 HIV-1 clinical isolates representing all major subtypes. GS-CA2 is highly lipophilic (LogD of 3.7) with low aqueous solubility (<0.01 mg/mL) and low predicted clearance (CL) in human hepatocytes (0.01 L/h/ kg). In rat and dog, GS-CA2 demonstrated low CL (<4% of liver blood flow). GS-CA2 PK in rat and dog exhibited sustained and slow drug release following a single SC administration. Factors including species, formulation, concentration, dose, volume, and number of injections were examined for the effect on systemic exposure over time. GS-CA2 plasma concentrations in dogs ( Figure 1 ) were maintained above the human plasma protein binding-adjusted EC 95 (4 nM) for the entire study duration (16 weeks).
Conclusion. GS-CA2 is a selective and first-in-class HIV capsid inhibitor with picomolar potency and potential to be clinically effective against a broad range of HIV-1 strains. In animals following a single SC injection, GS-CA2 maintained therapeutically relevant concentrations for >3 months. These nonclinical data support clinical development of GS-CA2 as a novel long-acting antiretroviral agent suitable for the treatment of HIV-1 infection.
